• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer
Biomed Res Int. 2022 May 5;2022:3647900. doi: 10.1155/2022/3647900. eCollection 2022.ABSTRACTAlthough many anticancer drugs have been developed for triple-negative breast cancer (TNBC) treatment, there are no obvious therapies. Moreover, the combination of epidermal growth factor receptor- (EGFR-) targeted therapeutics and classical chemotherapeutic drugs has been assessed in clinical trials for TNBC treatment, but those are not yet approved. Our serial studies for newly developed herbal medicine named SH003 provide evidence of its broad effectiveness in various cancers, especially on TNBC. The current study demonstrates a...
Source: Biomed Res - May 16, 2022 Category: Research Authors: Yu-Jeong Choi Kangwook Lee Ji-Hye Yoon Sung-Gook Cho Yun-Gyeong Kim Miso Jeong Hyun-Ha Hwang Seo Yeon Lee Se-Eun Jung Seong-Gyu Ko Source Type: research

Corrigendum to: A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study)
Jpn J Clin Oncol. 2021 Jul 23:hyab124. doi: 10.1093/jjco/hyab124. Online ahead of print.NO ABSTRACTPMID:34296283 | DOI:10.1093/jjco/hyab124
Source: Clinical Breast Cancer - July 23, 2021 Category: Cancer & Oncology Authors: Akihiko Shimomura Kenji Tamura Kiyo Tanaka Tomonori Mizutani Keita Sasaki Yuta Sekino Masataka Sawaki Tadahiko Shien Taro Shibata Hiroji Iwata Source Type: research

A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncollgy Group Study (JCOG1607, HERB TEA study)
Jpn J Clin Oncol. 2021 Jul 2:hyab101. doi: 10.1093/jjco/hyab101. Online ahead of print.ABSTRACTThe standard first-line treatment for patients with human epidermal growth factor 2-positive metastatic breast cancer is a combination therapy of trastuzumab, pertuzumab and docetaxel, and the standard second-line treatment is trastuzumab emtansine. However, it may be difficult for the elderly to maintain sufficient intensity of treatment due to severe adverse events of trastuzumab, pertuzumab and docetaxel. The aim of this trial is to confirm the non-inferiority of trastuzumab emtansine over trastuzumab, pertuzumab and docetaxel...
Source: Clinical Breast Cancer - July 3, 2021 Category: Cancer & Oncology Authors: Akihiko Shimomura Kenji Tamura Kiyo Tanaka Tomonori Mizutani Keita Sasaki Yuta Sekino Masataka Sawaki Tadahiko Shien Taro Shibata Hiroji Iwata Source Type: research